About Saegis Pharma
Saegis Pharma is a Healthcare company based in Half Moon Bay (United States) founded in 1999, and was acquired by Lundbeck in June 2006. Small molecule therapeutics for behavioural disorders were developed. Saegis Pharma has raised $52 million across 5 funding rounds from investors including Lundbeck, Stanley Medical Research Institute and Versant Ventures. Its focus areas include Life Sciences, Neurology, Drugs and Psychiatric. Its competitors include Alto Neuroscience, Supernus Pharmaceuticals and Neurovance; 2 of its 3 listed competitors have raised funding.
Company details
Saegis Pharma was founded in 1999 in Half Moon Bay, United States, focusing on the pharmaceutical sector. Small molecule therapeutics were developed for behavioural disorders, with a pipeline that included candidates for Alzheimers-associated dementia, mild cognitive impairment, attention deficit hyperactivity disorder, and schizophrenia. The company was acquired by Lundbeck in December 2006. A lead candidate, SGS518, was advanced as a 5HT6 serotonin receptor antagonist for cognitive impairment associated with schizophrenia.
- Headquarters Half Moon Bay, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website saegispharma.com
- Social LinkedIn
- Acquired by Lundbeck (Jun 2006)
Funding Insights of Saegis Pharma
Saegis Pharma has successfully raised a total of $52M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $6 million completed in June 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $52M
- Total Rounds 5
- Last Round Series B — $6M
- First Round $14M
(Jun 2001)
- Investors Count 6
All 5 funding rounds of Saegis Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2005 | $6M | Series B | – | – | – |
| May 2005 | $3.8M | Grant | – | – | |
| Jan 2004 | $2M | Series B | – | – | |
| Nov 2003 | $30M | Series B | – | – | |
| Jun 2001 | $14M | Series A | – | – |
7 investors in total: 7 institutional.
Investors in Saegis Pharma
Saegis Pharma has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Lundbeck, Stanley Medical Research Institute and Versant Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Investments are made in US life sciences and energy companies. | technologypartners.com | Palo Alto, United States | ||
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
| neuroventures.com | ||||
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Research on schizophrenia and bipolar disorder is supported. | 1989 | stanleyresearch.org | Rockville, United States | |
Drugs for CNS disorders are developed and advanced. | 1915 | lundbeck.com | Copenhagen, Denmark |
Investor details for Saegis Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Saegis Pharma
4 dated milestones of Saegis Pharma across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Saegis Pharma is founded.
- Funding First funding round of $14.0M.
- Funding Latest funding round, Series B, of $6.0M.
- Exit Acquired by Lundbeck.
Competitors of Saegis Pharma
Saegis Pharma has 3 listed competitors in our database, 2 of them funded. They include Alto Neuroscience, Supernus Pharmaceuticals and Neurovance.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| altoneuroscience.com | 2019 | San Francisco, United States | $144.72M | 34 | AI-driven drug discovery platform for neurological diseases based on patients biomarkers | |
| supernus.com | 2005 | Rockville, United States | 652 | Specialty pharmaceutical products for CNS diseases are developed and commercialized. | ||
| neurovance.com | 2011 | Cambridge, United States | $53.03M | 7 | Neurochemical modulators for ADHD treatment are developed by Neurovance. |
Detailed competitors of Saegis Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Saegis Pharma (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Saegis Pharma
Saegis Pharma was founded in 1999 and raised its 1st funding round 2 years after it was founded.
Saegis Pharma is headquartered in Half Moon Bay, United States. It is registered at Half Moon Bay, California, United States.
Saegis Pharma is a funded company, having raised a total of $52M across 5 funding rounds to date. The company's 1st funding round was a Series A of $14M, raised on Jun 2001.
Saegis Pharma was founded in 1999 in Half Moon Bay, United States, focusing on the pharmaceutical sector. Small molecule therapeutics were developed for behavioural disorders, with a pipeline that included candidates for Alzheimers-associated dementia, mild cognitive impairment, attention deficit hyperactivity disorder, and schizophrenia. The company was acquired by Lundbeck in December 2006. A lead candidate, SGS518, was advanced as a 5HT6 serotonin receptor antagonist for cognitive impairment associated with schizophrenia.
Saegis Pharma's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Neurovance.
Saegis Pharma has 7 investors. Key investors include Lundbeck, Stanley Medical Research Institute, Versant Ventures, Technology Partners, and Sofinnova.
Yes. Saegis Pharma was acquired by Lundbeck in June 2006.